GlassScriptPhysician profile
Nicole Borst
NPI 1659429173
$14,822.59
in general payments reported to CMS, 2019-2025
25 companies · $3,408 in 2025
The $3,408 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $335 · 2021: $1,649 · 2022: $2,724 · 2023: $2,804 · 2024: $3,274 · 2025: $3,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,069 · Education: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,068.61 |
| Education | $416.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,908.21 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $2,503.31 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $2,066.71 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,560.42 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,145.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $931.37 | 2022-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $712.92 | 2023-2025 | Acthar |
| Horizon Therapeutics Plc | $564.51 | 2020-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $547.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.99 | 2020-2024 | Cyltezo, Ofev |
| Glaxosmithkline, LLC. | $356.57 | 2022-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $201.43 | 2019-2025 | Orencia |
| Organon LLC | $194.84 | 2023-2025 | Renflexis, Hadlima |
| Janssen Scientific Affairs, LLC | $122.60 | 2021 | |
| Radius Health, INC. | $109.74 | 2021-2025 | Tymlos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $91.90 | 2019-2025 | Actemra |
| Lilly USA, LLC | $80.51 | 2019-2025 | Taltz |
| Genzyme Corporation | $54.97 | 2019-2023 | |
| Sobi, INC | $49.93 | 2019-2025 | |
| Bioventus LLC | $27.78 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $24.08 | 2025 | Purified Cortrophin Gel |
| Tonix Medicines, INC. | $19.34 | 2025 | Tonmya |
| Janssen Pharmaceuticals, INC | $17.80 | 2019 | |
| Tersera Therapeutics LLC | $16.57 | 2021 | |
| Aurinia Pharma U.S., INC. | $14.87 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Borst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.